We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
J. Clin. Oncol 2022 May 18;[EPub Ahead of Print], FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, MA Mouret-Reynier, JH Sohn, D Taylor, KK Harnden, H Khong, J Kocsis, F Dalenc, PM Dillon, S Babu, S Waters, I Deleu, JA García Sáenz, E Bria, M Cazzaniga, J Lu, P Aftimos, J Cortés, S Liu, G Tonini, D Laurent, N Habboubi, MG Conlan, A Bardia